Brendan Flannery

13.1k total citations · 1 hit paper
184 papers, 6.7k citations indexed

About

Brendan Flannery is a scholar working on Epidemiology, Infectious Diseases and Health. According to data from OpenAlex, Brendan Flannery has authored 184 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Epidemiology, 67 papers in Infectious Diseases and 31 papers in Health. Recurrent topics in Brendan Flannery's work include Influenza Virus Research Studies (98 papers), Respiratory viral infections research (91 papers) and Pneumonia and Respiratory Infections (37 papers). Brendan Flannery is often cited by papers focused on Influenza Virus Research Studies (98 papers), Respiratory viral infections research (91 papers) and Pneumonia and Respiratory Infections (37 papers). Brendan Flannery collaborates with scholars based in United States, Brazil and Kenya. Brendan Flannery's co-authors include Alicia M. Fry, Edward A. Belongia, Michael L. Jackson, Manjusha Gaglani, Richard K. Zimmerman, Arnold S. Monto, Huong Q. McLean, Mary Patricia Nowalk, Lisa A. Jackson and Jessie R. Chung and has published in prestigious journals such as New England Journal of Medicine, JAMA and Nature Communications.

In The Last Decade

Brendan Flannery

177 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Incidence of Pneumococcal Disease Due to Non–Pneumococcal Conjugate Vaccine (PCV7) Serotypes in the United States during the Era of Widespread PCV7 Vaccination, 1998–2004

2007 609 citations Brendan Flannery et al. The Journal of Infectious Diseases profile →

Peers

Countries citing papers authored by Brendan Flannery

Since Specialization

Citations

This map shows the geographic impact of Brendan Flannery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brendan Flannery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brendan Flannery more than expected).

Fields of papers citing papers by Brendan Flannery

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brendan Flannery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brendan Flannery. The network helps show where Brendan Flannery may publish in the future.

Co-authorship network of co-authors of Brendan Flannery

This figure shows the co-authorship network connecting the top 25 collaborators of Brendan Flannery. A scholar is included among the top collaborators of Brendan Flannery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brendan Flannery. Brendan Flannery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Estimating Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Using Linked Public Health Information Systems, California, 2023–2024 Season 2025 ·The Journal of Infectious Diseases ·Sophie Zhu, Joshua Quint, Tomás M. León, (unknown), (unknown), Cynthia Yen, Mark W. Tenforde, Brendan Flannery, Seema Jain, Robert Schechter, (unknown), Erin L. Murray	0
2	Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations 2025 ·Clinical Infectious Diseases ·Edward A. Belongia, Huong Q. Nguyen, David L. McClure, Nathaniel M. Lewis, Sascha Ellington, Brendan Flannery, Joshua G. Petrie	0
3	Anti–SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021–June 2022 2024 ·The Journal of Infectious Diseases ·Kelsey M. Sumner, Ruchi Yadav, (unknown), Ryan Sandford, (unknown), Sara Y. Tartof, Karen J. Wernli, Emily T. Martin, Manjusha Gaglani, Richard K. Zimmerman, H. Keipp Talbot, Carlos G. Grijalva, Edward A. Belongia, Jessie R. Chung, Eric Rogier, Melissa M. Coughlin, Brendan Flannery	4
4	Antibody Response to Symptomatic Infection With SARS‐CoV‐2 Omicron Variant Viruses, December 2021–June 2022 2024 ·Influenza and Other Respiratory Viruses ·Ryan Sandford, (unknown), (unknown), Kelsey M. Sumner, (unknown), Sara Y. Tartof, Karen J. Wernli, Emily T. Martin, Manjusha Gaglani, Richard K. Zimmerman, H. Keipp Talbot, Carlos G. Grijalva, Edward A. Belongia, Christina M. Carlson, Melissa M. Coughlin, Brendan Flannery, Brad D. Pearce, Eric Rogier	0
5	Influenza Vaccine Effectiveness Among Children: 2011–2020 2023 ·PEDIATRICS ·(unknown), Brendan Flannery, Manjusha Gaglani, Madhava Beeram, Karen J. Wernli, Michael L. Jackson, Emily T. Martin, Arnold S. Monto, Richard K. Zimmerman, Jonathan M. Raviotta, Edward A. Belongia, Huong Q. McLean, Sara Kim, Manish Patel, Jessie R. Chung	10
6	K‐medoids clustering of hospital admission characteristics to classify severity of influenza virus infection 2023 ·Influenza and Other Respiratory Viruses ·Aleda M. Leis, Erin McSpadden, Hannah E. Segaloff, Adam S. Lauring, Caroline Cheng, Joshua G. Petrie, Lois Lamerato, Manish M. Patel, Brendan Flannery, Jill M. Ferdinands, Carrie Karvonen‐Gutierrez, Arnold S. Monto, Emily T. Martin	3
7	Prior SARS‐CoV‐2 infection and COVID‐19 vaccine effectiveness against outpatient illness during widespread circulation of SARS‐CoV‐2 Omicron variant, US Flu VE network 2023 ·Influenza and Other Respiratory Viruses ·Sara Y. Tartof, Fagen Xie, Ruchi Yadav, Karen J. Wernli, Emily T. Martin, Edward A. Belongia, Manjusha Gaglani, Richard K. Zimmerman, H. Keipp Talbot, Natalie J. Thornburg, Brendan Flannery, (unknown)	8
8	Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020–May 2021 2022 ·Open Forum Infectious Diseases ·Alexia Couture, B. Casey Lyons, Megha Mehrotra, Lynn Sosa, Ngozi Ezike, Farah Ahmed, Catherine Brown, Stephanie Yendell, (unknown), Božena Katić, Anna B. Cope, (unknown), (unknown), (unknown), John R. Dunn, Lora Davis, Carrie Reed, Kristie E.N. Clarke, Brendan Flannery, Myrna Charles	17
9	Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021–2022 Influenza Season 2022 ·Clinical Infectious Diseases ·(unknown), Brendan Flannery, H. Keipp Talbot, Carlos G. Grijalva, Karen J. Wernli, C. Hallie Phillips, Arnold S. Monto, Emily T. Martin, Edward A. Belongia, Huong Q. McLean, Manjusha Gaglani, Manohar B. Mutnal, Krissy Moehling Geffel, Mary Patricia Nowalk, Sara Y. Tartof, Ana Florea, (unknown), Sara Kim, Manish M. Patel, Jessie R. Chung	32
10	Effectiveness of two and three mRNA COVID‐19 vaccine doses against Omicron‐ and Delta‐Related outpatient illness among adults, October 2021–February 2022 2022 ·Influenza and Other Respiratory Viruses ·Sara Kim, Jessie R. Chung, H. Keipp Talbot, Carlos G. Grijalva, Karen J. Wernli, Erika Kiniry, Emily T. Martin, Arnold S. Monto, Edward A. Belongia, Huong Q. McLean, Manjusha Gaglani, (unknown), Mary Patricia Nowalk, Krissy Moehling Geffel, Sara Y. Tartof, Ana Florea, Justin S. Lee, Mark W. Tenforde, Manish M. Patel, Brendan Flannery, (unknown)	11
11	Vaccine effectiveness against COVID‐19 among symptomatic persons aged ≥12 years with reported contact with COVID‐19 cases, February–September 2021 2022 ·Influenza and Other Respiratory Viruses ·Jessie R. Chung, Sara Kim, Edward A. Belongia, Huong Q. McLean, Jennifer P. King, Mary Patricia Nowalk, Richard K. Zimmerman, Krissy Moehling Geffel, Emily T. Martin, Arnold S. Monto, Lois Lamerato, Manjusha Gaglani, Eric P. Hoffman, Marcus Volz, Michael L. Jackson, Lisa A. Jackson, Manish Patel, Brendan Flannery	5
12	Burden of medically attended influenza infection and cases averted by vaccination – United States, 2016/17 through 2018/19 influenza seasons 2022 ·Vaccine ·Michael L. Jackson, C. Hallie Phillips, (unknown), Erika Kiniry, Lisa A. Jackson, Emily T. Martin, Arnold S. Monto, Huong Q. McLean, Edward A. Belongia, Manjusha Gaglani, Kayan Dunnigan, Chandni Raiyani, Kempapura Murthy, Brendan Flannery, Jessie R. Chung	2
13	The burden of influenza among Kenyan pregnant and postpartum women and their infants, 2015–2020 2022 ·Influenza and Other Respiratory Viruses ·Nancy A. Otieno, Bryan O. Nyawanda, Meredith McMorrow, Martina Oneko, (unknown), (unknown), Marc‐Alain Widdowson, Brendan Flannery, Sandra S. Chaves, Eduardo Azziz‐Baumgartner, Gideon O. Emukule	2
14	Consistency of self‐reported and documented historical influenza vaccination status of US healthcare workers 2022 ·Influenza and Other Respiratory Viruses ·Annette K. Regan, Meredith G. Wesley, Manjusha Gaglani, Sara Kim, Laura Edwards, Kempapura Murthy, Zuha Jeddy, Allison L. Naleway, Brendan Flannery, Fatimah S. Dawood, Holly C. Groom	10
15	Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults 2021 ·Influenza and Other Respiratory Viruses ·Sarah Spencer, Jessie R. Chung, Edward A. Belongia, Maria E. Sundaram, Jennifer K. Meece, Laura A. Coleman, Richard K. Zimmerman, Mary Patricia Nowalk, Krissy Moehling Geffel, Ted M. Ross, Chalise E. Carter, David K. Shay, Min Z. Levine, Justine S. Liepkalns, Jin Hyang Kim, Suryaprakash Sambhara, Mark G. Thompson, Brendan Flannery	7
16	Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011–2012 through 2018–2019 2021 ·Vaccine ·Michael Wu, Jessie R. Chung, Sara Kim, Michael L. Jackson, Lisa A. Jackson, Edward A. Belongia, Huong Q. McLean, Manjusha Gaglani, Michael Reis, Madhava Beeram, Emily T. Martin, Arnold S. Monto, Mary Patricia Nowalk, Richard K. Zimmerman, Tammy A. Santibanez, James A. Singleton, Manish M. Patel, Brendan Flannery	5
17	Clinical Symptoms Among Ambulatory Patients Tested for SARS-CoV-2 2020 ·Open Forum Infectious Diseases ·Jessie R. Chung, Sara Kim, Michael L. Jackson, Lisa A. Jackson, Edward A. Belongia, Jennifer P. King, Richard K. Zimmerman, Mary Patricia Nowalk, Emily T. Martin, Arnold S. Monto, Manjusha Gaglani, Michael Smith, Manish Patel, Brendan Flannery	7
18	Influenza vaccine effectiveness among outpatients in the US Influenza Vaccine Effectiveness Network by study site 2011‐2016 2020 ·Influenza and Other Respiratory Viruses ·G.K. Balasubramani, Mary Patricia Nowalk, Theresa M. Sax, Joe Suyama, (unknown), Charles R. Rinaldo, Emily T. Martin, Arnold S. Monto, Michael L. Jackson, Manjusha Gaglani, Brendan Flannery, Jessie R. Chung, Richard K. Zimmerman	7
19	Healthcare-seeking Behaviour for Common Infectious Disease-related Illnesses in Rural Kenya: A Community-based House-to-house Survey 2011 ·Journal of Health Population and Nutrition ·Deron C. Burton, Brendan Flannery, (unknown), Charles P. Larson, Jane Alaii, Xingyou Zhang, Mary J. Hamel, Robert F. Breiman, (unknown)	116
20	Brazilian experience with rapid monitoring of vaccination coverage during a national rubella elimination campaign. 2011 ·PubMed ·Antônia Maria da Silva Teixeira, (unknown), (unknown), (unknown), Ana Morice, Brendan Flannery	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact